市場調査レポート
商品コード
1405579

CTLA4(細胞傷害性Tリンパ球抗原4)阻害剤の世界市場 2024-2028

Global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market 2024-2028

出版日: | 発行: TechNavio | ページ情報: 英文 163 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
CTLA4(細胞傷害性Tリンパ球抗原4)阻害剤の世界市場 2024-2028
出版日: 2023年12月28日
発行: TechNavio
ページ情報: 英文 163 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

CTLA4(細胞傷害性Tリンパ球抗原4)阻害剤市場は2023-2028年に22億3,000万米ドル、予測期間中のCAGRは15.11%で成長すると予測されます。

当レポートでは、CTLA4(細胞傷害性Tリンパ球抗原4)阻害剤市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。CLTA4阻害剤の高い標的親和性と特異性、併用療法の人気の高まり、CLTA4阻害剤開発における戦略的提携などが市場を牽引しています。

市場範囲
基準年 2023
終了年 2028
予測期間 2024-2028
成長モメンタム 加速
前年比2024年 14.01%
CAGR 15.11%
増分額 22億3,000万米ドル

本調査では、今後数年間のCTLA4(細胞傷害性Tリンパ球抗原4)阻害剤市場の成長を牽引する主な理由の1つとして、CLTA4の研究適応拡大を挙げています。また、CLTA4阻害剤の特効薬指定やがんに対する意識の高まりは、市場の大きな需要につながると見込まれています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2023
  • 市場の見通し 2023-2028

第4章 市場規模実績

  • CTLA4(細胞傷害性Tリンパ球抗原4)阻害剤の世界市場 2018-2022
  • タイプセグメント分析 2018-2022
  • 流通チャネルセグメント分析 2018-2022
  • 地域別セグメント分析 2018-2022
  • 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • 比較:タイプ別
  • 単独療法:市場規模と予測 2023-2028
  • 併用療法:市場規模と予測 2023-2028
  • 市場機会:タイプ別

第7章 市場セグメンテーション:流通チャネル別

  • 市場セグメント
  • 比較:流通チャネル別
  • 病院薬局:市場規模と予測 2023-2028
  • 小売薬局:市場規模と予測 2023-2028
  • オンライン薬局:市場規模と予測 2023-2028
  • 市場機会:流通チャネル別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2023-2028
  • 欧州:市場規模と予測 2023-2028
  • アジア:市場規模と予測 2023-2028
  • 世界のその他の地域:市場規模と予測 2023-2028
  • 米国:市場規模と予測 2023-2028
  • ドイツ:市場規模と予測 2023-2028
  • カナダ:市場規模と予測 2023-2028
  • 英国:市場規模と予測 2023-2028
  • 中国:市場規模と予測 2023-2028
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Agenus Inc.
  • Akeso Inc.
  • AstraZeneca Plc
  • Bio Techne Corp.
  • BioNTech SE
  • Bristol Myers Squibb Co.
  • HBM Holdings Ltd.
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck and Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Shanghai Fosun Pharmaceutical Group Co. Ltd.
  • TRACON Pharmaceuticals Inc.
  • Xencor Inc.
  • XILIO THERAPEUTICS INC.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Historic Market Size - Data Table on global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market 2018 - 2022 ($ million)
  • Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits29: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits30: Chart on Type - Market share 2023-2028 (%)
  • Exhibits31: Data Table on Type - Market share 2023-2028 (%)
  • Exhibits32: Chart on Comparison by Type
  • Exhibits33: Data Table on Comparison by Type
  • Exhibits34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
  • Exhibits38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
  • Exhibits40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
  • Exhibits42: Market opportunity by Type ($ million)
  • Exhibits43: Data Table on Market opportunity by Type ($ million)
  • Exhibits44: Chart on Distribution Channel - Market share 2023-2028 (%)
  • Exhibits45: Data Table on Distribution Channel - Market share 2023-2028 (%)
  • Exhibits46: Chart on Comparison by Distribution Channel
  • Exhibits47: Data Table on Comparison by Distribution Channel
  • Exhibits48: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits49: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits50: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits51: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits52: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits53: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits54: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits55: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibits58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Market opportunity by Distribution Channel ($ million)
  • Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
  • Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits65: Chart on Geographic comparison
  • Exhibits66: Data Table on Geographic comparison
  • Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
  • Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibits92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibits93: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits95: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibits96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibits97: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits98: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
  • Exhibits103: Market opportunity By Geographical Landscape ($ million)
  • Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
  • Exhibits105: Impact of drivers and challenges in 2023 and 2028
  • Exhibits106: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits107: Overview on factors of disruption
  • Exhibits108: Impact of key risks on business
  • Exhibits109: Vendors covered
  • Exhibits110: Matrix on vendor position and classification
  • Exhibits111: Agenus Inc. - Overview
  • Exhibits112: Agenus Inc. - Product / Service
  • Exhibits113: Agenus Inc. - Key offerings
  • Exhibits114: Akeso Inc. - Overview
  • Exhibits115: Akeso Inc. - Product / Service
  • Exhibits116: Akeso Inc. - Key offerings
  • Exhibits117: AstraZeneca Plc - Overview
  • Exhibits118: AstraZeneca Plc - Product / Service
  • Exhibits119: AstraZeneca Plc - Key news
  • Exhibits120: AstraZeneca Plc - Key offerings
  • Exhibits121: Bio Techne Corp. - Overview
  • Exhibits122: Bio Techne Corp. - Business segments
  • Exhibits123: Bio Techne Corp. - Key offerings
  • Exhibits124: Bio Techne Corp. - Segment focus
  • Exhibits125: BioNTech SE - Overview
  • Exhibits126: BioNTech SE - Key offerings
  • Exhibits127: Bristol Myers Squibb Co. - Overview
  • Exhibits128: Bristol Myers Squibb Co. - Product / Service
  • Exhibits129: Bristol Myers Squibb Co. - Key news
  • Exhibits130: Bristol Myers Squibb Co. - Key offerings
  • Exhibits131: HBM Holdings Ltd. - Overview
  • Exhibits132: HBM Holdings Ltd. - Product / Service
  • Exhibits133: HBM Holdings Ltd. - Key offerings
  • Exhibits134: Innovent Biologics Inc. - Overview
  • Exhibits135: Innovent Biologics Inc. - Product / Service
  • Exhibits136: Innovent Biologics Inc. - Key offerings
  • Exhibits137: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
  • Exhibits138: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
  • Exhibits139: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
  • Exhibits140: Merck and Co. Inc. - Overview
  • Exhibits141: Merck and Co. Inc. - Business segments
  • Exhibits142: Merck and Co. Inc. - Key news
  • Exhibits143: Merck and Co. Inc. - Key offerings
  • Exhibits144: Merck and Co. Inc. - Segment focus
  • Exhibits145: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibits146: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits147: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits148: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Overview
  • Exhibits149: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Business segments
  • Exhibits150: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Key offerings
  • Exhibits151: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Segment focus
  • Exhibits152: TRACON Pharmaceuticals Inc. - Overview
  • Exhibits153: TRACON Pharmaceuticals Inc. - Product / Service
  • Exhibits154: TRACON Pharmaceuticals Inc. - Key offerings
  • Exhibits155: Xencor Inc. - Overview
  • Exhibits156: Xencor Inc. - Product / Service
  • Exhibits157: Xencor Inc. - Key news
  • Exhibits158: Xencor Inc. - Key offerings
  • Exhibits159: XILIO THERAPEUTICS INC. - Overview
  • Exhibits160: XILIO THERAPEUTICS INC. - Product / Service
  • Exhibits161: XILIO THERAPEUTICS INC. - Key offerings
  • Exhibits162: Inclusions checklist
  • Exhibits163: Exclusions checklist
  • Exhibits164: Currency conversion rates for US$
  • Exhibits165: Research methodology
  • Exhibits166: Validation techniques employed for market sizing
  • Exhibits167: Information sources
  • Exhibits168: List of abbreviations
目次
Product Code: IRTNTR72722

Abstract

The ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is forecasted to grow by USD 2,230 mn during 2023-2028, accelerating at a CAGR of 15.11% during the forecast period. The report on the ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of CLTA4 inhibitors, growing popularity of combination therapy, and strategic alliances in developing CLTA4 inhibitors.

Market Scope
Base Year2023
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 202414.01%
CAGR15.11%
Incremental Value$2230mn

Technavio's CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is segmented as below:

By Type

  • Monotherapy
  • Combination therapy

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the expansion of research indications of CLTA4 as one of the prime reasons driving the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market growth during the next few years. Also, special drug designations of CLTA4 inhibitors and increasing awareness about cancer will lead to sizable demand in the market.

The report on the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market covers the following areas:

  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market sizing
  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market forecast
  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market vendors that include AstraZeneca Plc, Bio Techne Corp., BioNTech SE, Bristol Myers Squibb Co., HBM Holdings Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Xencor Inc., Agenus Inc., Akeso Inc., Innovent Biologics Inc., Molecular Templates Inc., TRACON Pharmaceuticals Inc., and XILIO THERAPEUTICS INC.. Also, the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors market 2018 - 2022
  • Exhibit 18: Historic Market Size - Data Table on global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market 2018 - 2022 ($ million)
  • 4.2 Type Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • 4.3 Distribution Channel Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
  • 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

  • 6.1 Market segments
  • Exhibit 30: Chart on Type - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
  • 6.2 Comparison by Type
  • Exhibit 32: Chart on Comparison by Type
  • Exhibit 33: Data Table on Comparison by Type
  • 6.3 Monotherapy - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibit 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
  • Exhibit 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
  • 6.4 Combination therapy - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
  • Exhibit 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
  • Exhibit 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
  • 6.5 Market opportunity by Type
  • Exhibit 42: Market opportunity by Type ($ million)
  • Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments
  • Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
  • Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
  • 7.2 Comparison by Distribution Channel
  • Exhibit 46: Chart on Comparison by Distribution Channel
  • Exhibit 47: Data Table on Comparison by Distribution Channel
  • 7.3 Hospital pharmacies - Market size and forecast 2023-2028
  • Exhibit 48: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 49: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 50: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 51: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • 7.4 Retail pharmacies - Market size and forecast 2023-2028
  • Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • 7.5 Online pharmacies - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • 7.6 Market opportunity by Distribution Channel
  • Exhibit 60: Market opportunity by Distribution Channel ($ million)
  • Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
  • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 Germany - Market size and forecast 2023-2028
  • Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.9 Canada - Market size and forecast 2023-2028
  • Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • 9.10 UK - Market size and forecast 2023-2028
  • Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 9.11 China - Market size and forecast 2023-2028
  • Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 103: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 Agenus Inc.
  • Exhibit 111: Agenus Inc. - Overview
  • Exhibit 112: Agenus Inc. - Product / Service
  • Exhibit 113: Agenus Inc. - Key offerings
  • 12.4 Akeso Inc.
  • Exhibit 114: Akeso Inc. - Overview
  • Exhibit 115: Akeso Inc. - Product / Service
  • Exhibit 116: Akeso Inc. - Key offerings
  • 12.5 AstraZeneca Plc
  • Exhibit 117: AstraZeneca Plc - Overview
  • Exhibit 118: AstraZeneca Plc - Product / Service
  • Exhibit 119: AstraZeneca Plc - Key news
  • Exhibit 120: AstraZeneca Plc - Key offerings
  • 12.6 Bio Techne Corp.
  • Exhibit 121: Bio Techne Corp. - Overview
  • Exhibit 122: Bio Techne Corp. - Business segments
  • Exhibit 123: Bio Techne Corp. - Key offerings
  • Exhibit 124: Bio Techne Corp. - Segment focus
  • 12.7 BioNTech SE
  • Exhibit 125: BioNTech SE - Overview
  • Exhibit 126: BioNTech SE - Key offerings
  • 12.8 Bristol Myers Squibb Co.
  • Exhibit 127: Bristol Myers Squibb Co. - Overview
  • Exhibit 128: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 129: Bristol Myers Squibb Co. - Key news
  • Exhibit 130: Bristol Myers Squibb Co. - Key offerings
  • 12.9 HBM Holdings Ltd.
  • Exhibit 131: HBM Holdings Ltd. - Overview
  • Exhibit 132: HBM Holdings Ltd. - Product / Service
  • Exhibit 133: HBM Holdings Ltd. - Key offerings
  • 12.10 Innovent Biologics Inc.
  • Exhibit 134: Innovent Biologics Inc. - Overview
  • Exhibit 135: Innovent Biologics Inc. - Product / Service
  • Exhibit 136: Innovent Biologics Inc. - Key offerings
  • 12.11 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Exhibit 137: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
  • Exhibit 138: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
  • Exhibit 139: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
  • 12.12 Merck and Co. Inc.
  • Exhibit 140: Merck and Co. Inc. - Overview
  • Exhibit 141: Merck and Co. Inc. - Business segments
  • Exhibit 142: Merck and Co. Inc. - Key news
  • Exhibit 143: Merck and Co. Inc. - Key offerings
  • Exhibit 144: Merck and Co. Inc. - Segment focus
  • 12.13 Ono Pharmaceutical Co. Ltd.
  • Exhibit 145: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibit 146: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 147: Ono Pharmaceutical Co. Ltd. - Key offerings
  • 12.14 Shanghai Fosun Pharmaceutical Group Co. Ltd.
  • Exhibit 148: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Overview
  • Exhibit 149: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Business segments
  • Exhibit 150: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Key offerings
  • Exhibit 151: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Segment focus
  • 12.15 TRACON Pharmaceuticals Inc.
  • Exhibit 152: TRACON Pharmaceuticals Inc. - Overview
  • Exhibit 153: TRACON Pharmaceuticals Inc. - Product / Service
  • Exhibit 154: TRACON Pharmaceuticals Inc. - Key offerings
  • 12.16 Xencor Inc.
  • Exhibit 155: Xencor Inc. - Overview
  • Exhibit 156: Xencor Inc. - Product / Service
  • Exhibit 157: Xencor Inc. - Key news
  • Exhibit 158: Xencor Inc. - Key offerings
  • 12.17 XILIO THERAPEUTICS INC.
  • Exhibit 159: XILIO THERAPEUTICS INC. - Overview
  • Exhibit 160: XILIO THERAPEUTICS INC. - Product / Service
  • Exhibit 161: XILIO THERAPEUTICS INC. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 162: Inclusions checklist
  • Exhibit 163: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 164: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 165: Research methodology
  • Exhibit 166: Validation techniques employed for market sizing
  • Exhibit 167: Information sources
  • 13.5 List of abbreviations
  • Exhibit 168: List of abbreviations